GSK plc (GSK), with its development partner iTeos Therapeutics (ITOS), confirmed it is ending the development program for belrestotug, an anti-TIGIT monoclonal antibody. “The decision is based on new interim analyses from the phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which did not meet the established efficacy criteria for continued development. As a result, the collaboration and all belrestotug-containing study cohorts are ending,” GSK stated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- iTeos: GALAXIES Lung-201 did not meet criteria for meaninful improvements in PFS
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- White House publishes Trump executive order aimed at lowering drug prices
- Trump to sign executive order aimed at lowering drug prices
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue